Payment overview · 2025
General Payments
$222.74
10 reported records · 10 companies
Healthcare provider profile · identity verified
Ines Rodriguez, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MIAMI, FL · NPI 1659609410
Verified facts
What the public records show
CMS Open Payments records show Ines Rodriguez, APRN received $222.74 in general payments during 2025 across 10 reported records.
Actelion Pharmaceuticals US, Inc. accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $40.80 | 18.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.08 | 10.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.11 | 10.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.40 | 10.1% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $22.06 | 9.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.80 | 8.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.66 | 8.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.51 | 8.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.32 | 7.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.00 | 7.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $222.74 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $40.80 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 70 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 45 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
70 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 414 | 144 |
| Metformin Hcl | Metformin Hcl | 304 | 104 |
| Losartan Potassium | Losartan Potassium | 237 | 89 |
| Omeprazole | Omeprazole | 212 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 205 | 73 |
| Gabapentin | Gabapentin | 199 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 187 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 183 | 67 |
| Simvastatin | Simvastatin | 180 | 66 |
| Lisinopril | Lisinopril | 171 | 56 |
| Diclofenac Sodium | Diclofenac Sodium | 135 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 45 |
| Famotidine | Famotidine | 127 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 39 |
| Montelukast Sodium | Montelukast Sodium | 111 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 33 |
| Alendronate Sodium | Alendronate Sodium | 89 | 31 |
| Glipizide | Glipizide | 87 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 79 | 36 |
| Memantine Hcl | Memantine Hcl | 71 | 26 |
| Eliquis | Apixaban | 70 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 68 | 43 |
| Glimepiride | Glimepiride | 68 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 24 |
| Folic Acid | Folic Acid | 62 | 26 |
| Furosemide | Furosemide | 55 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 23 |
| Carvedilol | Carvedilol | 46 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 19 |
| Ibuprofen | Ibuprofen | 45 | 35 |
| Jardiance | Empagliflozin | 45 | 13 |
| Latanoprost | Latanoprost | 44 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 44 | 20 |
| Nifedipine Er | Nifedipine | 43 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | 24 |
| Allopurinol | Allopurinol | 42 | 17 |
| Mirtazapine | Mirtazapine | 42 | 16 |
| Sucralfate | Sucralfate | 42 | 11 |
| Enalapril Maleate | Enalapril Maleate | 41 | 14 |
| Ketoconazole | Ketoconazole | 41 | 12 |
| Ezetimibe | Ezetimibe | 40 | 18 |
| Clobetasol Propionate | Clobetasol Propionate | 39 | 12 |
| Ozempic | Semaglutide | 39 | suppressed |
| Azithromycin | Azithromycin | 38 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 16 |
| Januvia | Sitagliptin Phosphate | 37 | 12 |
| Sertraline Hcl | Sertraline Hcl | 37 | 20 |
| Sildenafil Citrate | Sildenafil Citrate | 34 | suppressed |
| Atenolol | Atenolol | 33 | 15 |
| Irbesartan | Irbesartan | 33 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 32 | 17 |
| Donepezil Hcl | Donepezil Hcl | 32 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 27 |
| Chlorthalidone | Chlorthalidone | 30 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | 12 |
| Tadalafil | Tadalafil | 30 | 11 |
| Ammonium Lactate | Ammonium Lactate | 29 | 13 |
| Trazodone Hcl | Trazodone Hcl | 29 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | 11 |
| Finasteride | Finasteride | 26 | 11 |
| Tradjenta | Linagliptin | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | 11 |
| Nystatin | Nystatin | 25 | suppressed |
| Mupirocin | Mupirocin | 24 | 18 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | 16 |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Pentoxifylline | Pentoxifylline | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Ciclopirox | Ciclopirox | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Glipizide Er | Glipizide | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 14 |
| Clonazepam | Clonazepam | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $222.74 · 10 records | Actelion Pharmaceuticals US, Inc. | AIRSUPRA, BEYFORTUS, ELIQUIS, GEMTESA, JARDIANCE, Kerendia, OPSUMIT, The Cologuard Plus Collection Kit | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error